*Dipartimento di Scienze Oftalmologiche, Università di Roma "La Sapienza", Roma, Italy ‡U.O.C. Oculistica-Azienda Ospedaliera San Camillo-Forlanini, Roma, Italy §Azienda Ospedaliera S. Maria della Misericordia, Udine, Italy ∥Clinica Oculistica Università degli Studi, L'Aquila ¶Casa di Cura del Policlinico, Milano, Italy †Faculdad de Medicina de la Universidad de Buenos Aires, Argentina.
J Glaucoma. 2013 Jan;22(1):5-9. doi: 10.1097/IJG.0b013e3182311db4.
The purpose of the study was to assess the effect of ibopamine (3,4 di-isobutyrrylester of N-methyldopamine), a D1-dopamine agonist, on intraocular pressure (IOP) in offspring of parents with primary openangle glaucoma as a consequence of outflow structures impairment.
We included participants aged between 8 and 40 years: group 1, 163 offspring of at least 1 parent with primary openangle glaucoma with normal IOP and without glaucomatous damages; group 2, 108 offspring of healthy parents (without history or existing glaucoma). Ibopamine test was performed by instilling 2 drops, 5 minutes apart, in both eyes followed by repeated IOP measurements over a 45-minute period. The test is considered positive if there is an IOP increase of ≥3 mm Hg 45 minutes after instillation.
Baseline IOP before the test was 15.73±2.31 and 15.31±1.86 mm Hg in groups 1 and 2, respectively. Test was positive in 44.33% of cases in group 1 with a mean increase in IOP of 5.57 mm Hg (P<0.001), whereas in all participants of group 2 the test was negative with even 1 to 2 mm Hg IOP reduction.
D1-dopaminergic stimulation due to ibopamine increases IOP as a result of increased production of the aqueous humor in participants with an impaired outflow. The study showed that offspring of at least 1 parent with primary openangle glaucoma--offspring without glaucomatous damages--show an increase of IOP after ibopamine administration, which signifies an impaired function of outflow structures and, therefore, a predisposition to intraocular hypertension and possible glaucoma.
本研究旨在评估 3,4-二异丁酰基-N-甲基多巴胺（一种 D1-多巴胺激动剂）对因流出道结构损伤而患原发性开角型青光眼的父母的后代眼内压（IOP）的影响。
我们纳入了年龄在 8 至 40 岁之间的参与者：第 1 组，163 名至少有 1 名患有原发性开角型青光眼且 IOP 正常且无青光眼损害的父母的后代；第 2 组，108 名健康父母（无青光眼病史或现有青光眼）的后代。通过在双眼内各滴 2 滴，间隔 5 分钟，然后在 45 分钟内重复测量 IOP，进行伊博胺试验。如果滴眼后 45 分钟 IOP 升高≥3mmHg，则试验被认为是阳性。
试验前的基础 IOP 在第 1 组和第 2 组中分别为 15.73±2.31mmHg 和 15.31±1.86mmHg。第 1 组中 44.33%的病例试验阳性，IOP 平均升高 5.57mmHg（P<0.001），而第 2 组的所有参与者试验均为阴性，甚至眼压降低 1 至 2mmHg。
伊博胺引起的 D1-多巴胺能刺激会增加房水的产生，从而导致流出受阻的参与者的 IOP 升高。该研究表明，至少有 1 名患有原发性开角型青光眼的父母的后代（无青光眼损害的后代）在给予伊博胺后眼压升高，这表明流出道结构功能受损，因此易患眼内高压和可能的青光眼。
